OS Therapies

CompanyUnited States

OS Therapies develops one asset, in phase 2 (daznelimgene lisbac in pulmonary metastatic osteosarcoma). Mostly vaccine acting on ERBB2; based in the United States.

1
Asset
Furthest stage: Phase 2; 0
Trials: 0
Signals

Pipeline

1

daznelimgene lisbac
Listeria-based immunotherapy targeting HER2-expressing cancer cells.
Phase 2, Vaccine, ERBB2, pulmonary metastatic osteosarcoma

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Similar companies3